

**1 PATIENT INFORMATION:**

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Alt. Phone: \_\_\_\_\_  
 Email: \_\_\_\_\_  
 DOB: \_\_\_\_\_ Gender:  M  F Caregiver: \_\_\_\_\_  
 Height: \_\_\_\_\_ Weight: \_\_\_\_\_ Allergies: \_\_\_\_\_

**2 PRESCRIBER INFORMATION:**

Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 NPI: \_\_\_\_\_ DEA: \_\_\_\_\_  
 Tax I.D.: \_\_\_\_\_  
 Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_

**3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)**

Date of Diagnosis: \_\_\_\_\_  
 Crohn's Disease  Ulcerative Colitis  Irritable Bowel Syndrome  
 ICD-10: \_\_\_\_\_  
 Other: \_\_\_\_\_  
 Serious or active infection present?  Yes  No  
 Hep B ruled out or treatment started?  Yes  No  
 TB Test:  Positive  Negative Date: \_\_\_\_\_

Prior Failed Treatments:	Indicate Drug Name and Length of Treatment:
<input type="checkbox"/> 5-ASA	_____
<input type="checkbox"/> Biologics	_____
<input type="checkbox"/> Corticosteroids	_____
<input type="checkbox"/> Immunosuppressants	_____
<input type="checkbox"/> Methotrexate	_____
<input type="checkbox"/> Surgery	_____
<input type="checkbox"/> Other	_____

**If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.**

**4 INJECTION TRAINING:**  To Be Administered by Pharmacist (State of Missouri Only)  Pharmacist to Provide Training  Patient Trained in MD Office  Manufacturer Nurse Support

**5 PICK UP OR DELIVERY:**  Delivery to Patient's Home  Delivery to Physician's Office  Pharmacy to Coordinate

**6 INSURANCE INFORMATION:** Please Include Front and Back Copies of Pharmacy and Medical Card

**PRESCRIPTION INFORMATION:** (Please be sure to choose both induction and maintenance dose where applicable)

Medication	Dosage & Strength	Direction	QTY	Refills
<input type="checkbox"/> <b>CIMZIA®</b>	<input type="checkbox"/> Prefilled Syringe Starter Kit <input type="checkbox"/> 200mg/ml Prefilled Syringe <input type="checkbox"/> 200mg Lyophilized Powder	<input type="checkbox"/> <b>Induction Dose:</b> Inject 400mg SC on day 1, 14 and 28 <input type="checkbox"/> <b>Maintenance:</b> Inject 400mg SC every 4 weeks <input type="checkbox"/> _____	6 2	0
<input type="checkbox"/> <b>HUMIRA®</b>	<input type="checkbox"/> Crohn's Disease/Ulcerative Colitis 80mg/0.8ml Starter Package <input type="checkbox"/> Crohn's Disease/Ulcerative Colitis 40mg/0.4ml Starter Package <input type="checkbox"/> 40mg/0.4ml Pen <input type="checkbox"/> 40mg/0.4ml Prefilled Syringe	<input type="checkbox"/> <b>Induction Dose:</b> <input type="checkbox"/> Inject two 80mg Pens SC on day 1, then one 80mg Pen SC on day 15 <input type="checkbox"/> Inject one 80mg Pen SC on day 1, then 80mg Pen SC on day 2, then one 80mg Pen SC on day 15 <input type="checkbox"/> <b>Maintenance:</b> Inject 40mg SC every other week <input type="checkbox"/> _____ <input type="checkbox"/> Patient has signed HUMIRA Complete form <i>All strengths and dosages listed are Humira® Citrate Free</i>	3 6 2	0 0
<input type="checkbox"/> <b>SIMPONI®</b>	<input type="checkbox"/> 100mg/ml Smartject® Autoinjector <input type="checkbox"/> 100mg/ml Prefilled Syringe	<input type="checkbox"/> <b>Induction Dose:</b> Inject 200mg SC at week 0, 100mg SC at week 2 and then switch to maintenance dose <input type="checkbox"/> <b>Maintenance:</b> Inject 100mg SC every 4 weeks	3 1	0
<input type="checkbox"/> <b>STELARA®</b>	<input type="checkbox"/> 130mg/26ml Vial <input type="checkbox"/> 45mg/0.5ml Prefilled Syringe <input type="checkbox"/> 90mg/ml Prefilled Syringe <input type="checkbox"/> 45mg/0.5ml Vial	<input type="checkbox"/> <b>Induction Dose:</b> Patient Weight <55kg: 260mg; >55kg to 85kg: 390mg; >85 kg: 520mg administered IV <input type="checkbox"/> <b>Maintenance Dose:</b> Inject 90mg SC 8 weeks after the initial intravenous dose, then every 8 weeks thereafter	1	0
<input type="checkbox"/> <b>UCERIS®</b>	<input type="checkbox"/> 9mg Tablets	<input type="checkbox"/> Take one tablet daily in the morning with or without food	30	1
<input type="checkbox"/> <b>XELJANZ®</b>	<input type="checkbox"/> 5mg Tablets <input type="checkbox"/> 10mg Tablets	<input type="checkbox"/> <b>Induction Dose:</b> Take 10mg orally twice daily for 8 weeks <input type="checkbox"/> <b>Maintenance Dose:</b> Take 5mg orally twice daily <input type="checkbox"/> <b>Maintenance Dose:</b> Take 10mg orally twice daily <input type="checkbox"/> _____ <i>Severe renal or moderate hepatic impairment: half the total daily dosage recommended for patients with normal renal and hepatic function</i>		
<input type="checkbox"/> <b>XIFAXAN®</b>	<input type="checkbox"/> 550mg Tablets	<input type="checkbox"/> Take one tablet three times daily for 14 days	42	
<input type="checkbox"/> _____	_____	_____		

**PRESCRIBER SIGNATURE:** I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Substitution Permitted**

**Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.